New government subsidised treatment options for some melanoma patients
As of 1 February 2024, Australians with unresectable or metastatic melanoma will have a new treatment option subsidised by the Pharmaceutical Benefits Scheme (PBS) with Opdualag (nivolumab/relatlimab) becoming available to patients at a government-subsidised price. The treatment is a combination of immunotherapies designed to help the body fight melanoma and the new listing is expected […]
New government subsidised treatment options for some melanoma patients Read More »
